story of the week
Survival in Patients With HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated With a Cyclin-Dependent Kinase 4/6 Inhibitor Plus Fulvestrant
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Lancet Oncol 2021 Oct 14;[EPub Ahead of Print], JJ Gao, J Cheng, TM Prowell, E Bloomquist, S Tang, SB Wedam, M Royce, D Krol, C Osgood, G Ison, R Sridhara, R Pazdur, JA Beaver, L Amiri-KordestaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.